Recently, the winners of two highly anticipated awards in the domestic capital market — the "Most Valuable Listed Company Golden Bull Award" and the "China Listed Company Value Awards" — were announced. Baheal  Medical (301015.SZ) stood out among thousands of listed companies, winning the titles of "Most Valuable Investment Golden Bull Award 2023" and "Top 50 GEM Listed Companies by Value." These accolades highlight the capital market's strong recognition of the company's exceptional performance, value return capabilities, and growth potential.

As one of the most authoritative and credible awards in China's capital market, the "Golden Bull Award" for listed companies is an integral part of the Golden Bull series organized by China Securities Journal, a subsidiary of Xinhua News Agency. Established in 1999, it is considered the gold standard for measuring high-quality development among listed companies, often referred to as the "Oscars" of the financial sector due to its stringent criteria and professional evaluation process. Thanks to its outstanding profitability and strong growth potential, Baheal Pharma has been honored with the "Most Valuable Investment Golden Bull Award 2023.

At the same time, Baheal Pharma has been recognized in the "18th China Listed Company Value Awards," organized by Securities Times, a subsidiary of People’s Daily. This event aims to recognize leading listed companies with excellent fundamentals, active social responsibility practices, and exemplary corporate governance. It has become an authoritative selection process that sets a benchmark for value investing in the capital market. Due to its outstanding performance in management, financial results, innovation capability, market influence, and social responsibility, Baheal Pharma has been named one of the "Top 50 GEM Listed Companies by Value."

As a platform supporting original innovation in the pharmaceutical industry, Baheal Medical has demonstrated steady growth since entering the capital market. The company's core products have consistently maintained their growth vitality, and its brand effect has gradually expanded. Strategically, Baheal has acquired pharmaceutical manufacturing firms, extending its industry chain upstream to the production end. This move has successfully established a dual-engine development model of "manufacturing" and "commercialization," injecting continuous momentum into the company's long-term development. Baheal Pharma has also bolstered its innovative collaboration with its parent company, bringing multiple groundbreaking drugs and medical devices to clinical use. 

In the first half of 2024, the company reported revenues of 3.595 billion yuan and net profits attributable to shareholders of 369 million yuan. Over the past three years, Baheal 's compound annual growth rate of net profit has reached an impressive 34.01%, underscoring its robust growth momentum. In addition to its consistent operational performance, Baheal places a strong emphasis on delivering returns to shareholders. Since its IPO, the company has regularly issued cash dividends, ensuring that investors share in its success. This commitment has significantly enhanced both its corporate value and its recognition in the capital market.

Looking ahead, Baheal Medical is committed to driving new productivity in the healthcare sector through continual innovation. The company will focus on enhancing operational quality and core competitiveness, aiming to elevate its brand value in the capital market. By achieving sustainable and high-quality growth, Baheal aims to deliver greater value and returns to its shareholders and investors.